SubHero Banner

Kisqali® (ribociclib) – New drug approval

March 13, 2017 – Novartis announced the FDA approval of Kisqali (ribociclib), indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Download PDF